Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?
about
MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.Combined small cell lung carcinoma and giant cell carcinoma: a case report.Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.Opening a Chromatin Gate to Metastasis.The impact of immunohistochemistry on the classification of lung tumors.Silibinin: a potential old drug for cancer therapy.Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.Family matters: How MYC family oncogenes impact small cell lung cancer.Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.Recalcitrant small cell lung cancer: the argument for optimism.Emerging strategies for the treatment of advanced small cell lung cancer.State-of-the-art considerations in small cell lung cancer brain metastases.Unraveling the genomic complexity of small cell lung cancer.Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies.Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer.Small-cell lung cancer: what we know, what we need to know and the path forward.Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models.Intratumoral heterogeneity of Notch1 expression in small cell lung cancer.Small cell lung cancer: updates and new concepts.Immune checkpoint inhibitors and small cell lung cancer: what’s new?Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients.Comparison and discussion of the treatment guidelines for small cell lung cancer.
P2860
Q37718370-71F6EA2E-FFAF-4A03-9D73-A6161D145D1DQ37733342-77B65752-2AE0-43E9-874C-7033480E93F0Q38753586-713B4368-0444-4428-9A7D-0668BB5DCF59Q38758025-1E7D7348-401F-4060-99D7-1165F04E9C48Q38822314-B618F91C-9C4D-446E-9EE8-48AFE88884A2Q38881726-ECA0CCF4-6736-42AF-8695-8FD2FA70679EQ38992148-D90D1FB0-4EEF-48A9-8736-0C346FDFEB08Q39019412-129A0017-5682-4D8B-9A38-DD623D8F6EDCQ39454070-235FE9F9-081C-46A3-AF62-07248BC8507CQ40208474-8EFA599F-96B4-47BD-84C8-49A940D382DFQ41466400-D3EDC81B-478A-4EDD-8565-BD9312DFFD9DQ42362314-1DE0263F-7C9F-42AC-B849-2C9CD96D60FCQ42369314-DFD418E3-C922-49F9-96E4-8B5CFDAFF5C7Q42378525-35228EBD-5C8B-4F82-A943-2149DAFF4C64Q42398708-1915D4E0-95AF-42C5-BC58-D84CCE591C37Q47161308-4AA4CC00-3562-42D9-85C3-216D59592420Q47163002-38C5C3AB-914B-430D-BC2B-6076DD6C0D81Q47184289-4E20B9D4-982F-4851-B1E6-7AF470B5334DQ47595394-4CF415C0-3D1A-4637-9562-EF9C9094CB1FQ53476716-184F5A4C-5DC5-41B1-96BE-BF31CBD41419Q53702193-3F23BD75-0D4D-4F59-804B-438A902950F8Q55036860-23AB848C-300E-4F6C-A148-223CFC6A259DQ55084975-FAE22759-A1A6-41E6-97EE-792C2A5A1819Q55287013-D49AABBB-9445-478A-8C40-39ACF8817B7BQ55419014-DE8E114D-F8BF-4F53-844E-BCF2BB558A76Q55516294-2186FA27-DD29-4BE2-8C23-8EDFDFF1AB0A
P2860
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Small Cell Lung Cancer: Can Re ...... slated into Improved Outcomes?
@ast
Small Cell Lung Cancer: Can Re ...... slated into Improved Outcomes?
@en
type
label
Small Cell Lung Cancer: Can Re ...... slated into Improved Outcomes?
@ast
Small Cell Lung Cancer: Can Re ...... slated into Improved Outcomes?
@en
prefLabel
Small Cell Lung Cancer: Can Re ...... slated into Improved Outcomes?
@ast
Small Cell Lung Cancer: Can Re ...... slated into Improved Outcomes?
@en
P2093
P2860
P50
P1476
Small Cell Lung Cancer: Can Re ...... slated into Improved Outcomes?
@en
P2093
Adi F Gazdar
Afshin Dowlati
Alexander Augustyn
Anna F Farago
Anton Berns
Ben J Slotman
Beverly A Teicher
Caicun Zhou
Camilla Laulund Christensen
Christine L Hann
P2860
P304
P356
10.1016/J.JTHO.2016.01.012
P50
P577
2016-01-29T00:00:00Z